The ASCENT trial confirmed the efficacy of sacituzumab govitecan in HER2-low metastatic BC, showing a significantly longer PFS (6.2 vs. 2.9 months, hazard ratio 0.44, 95% CI: 0.27–0.72, p = 0.002) and OS (14 vs. 8.7 months, hazard ratio 0.43, 95% CI: 0.28–0.67, p < 0.001) with sacituzumab govitecan over the CT of physician’s choice [114]. Here, ERBB2 is linked to breast cancer.